Persisting decline in depression treatment after FDA warnings

Area of Science:

• Psychiatry
• Public Health
• Health Services Research

Background:

• The U.S. Food and Drug Administration (FDA) issued advisories and warnings regarding antidepressant use in pediatric patients (2003) and young adults (2007) due to suicidality risks.
• These warnings led to immediate, unintended declines in depression diagnosis and treatment for pediatric populations, with spillover effects observed in adults.

Purpose of the Study:

• To investigate whether the initial declines in depression care for pediatric, young adult, and adult patients continued after the FDA advisories.
• To assess the long-term impact of FDA antidepressant warnings on depression diagnosis and treatment patterns.

Main Methods:

• Utilized time series analyses on a national integrated managed care claims database (July 1999–June 2007).
• Compared post-advisory depression care trends with pre-advisory patterns across pediatric, young adult, and adult cohorts.
• Analyzed depression diagnoses, antidepressant/antipsychotic/anxiolytic prescriptions, and psychotherapy visits.

Main Results:

• Significant reductions in new depression diagnoses persisted across all age groups (pediatric: 44%, young adults: 37%, adults: 29%).
• Selective serotonin reuptake inhibitor (SSRI) use decreased, while serotonin-norepinephrine reuptake inhibitor (SNRI) use increased in adults.
• Psychotherapy utilization increased significantly for adults but not for pediatric cases.

Conclusions:

• The study concludes that diagnosis decreases and treatment changes following FDA antidepressant warnings are persistent, substantial, and widespread.
• Substitute treatments did not fully compensate for the decline in care for pediatric and young adult patients.
• Policy interventions are necessary to address the unintended negative consequences of reduced depression treatment.